Examination of efficacy and safety treated by denosumab or zoledronate in glucocorticoid-induced osteoporosis

Examination of efficacy and safety treated by denosumab or zoledronate in glucocorticoid-induced osteoporosis - Efficacy and safety treated by denosumab orzoledronate in GIO

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035844

Enrollment

Registered

2019-02-13

Start date

2019-02-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucocorticoid-induced osteoporosis

Interventions

denosumab group zoledronate group

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1 GIO patients who are more than 20 years old 2 Patients who agree with this study

Exclusion criteria

Exclusion criteria: 1 Patients who have taken denosumab or zoledronate before 2 Patients who are allergic to denosumab or zoledronate 3 Pregnant or breast-feeding patients 4 Renal failure (Ccr is less than 35 mL/min) 5 Dehydrated state 6 Hypocalcemia

Design outcomes

Primary

Measure	Time frame
Bone mineral density at 60 months after treatment	—

Countries

Japan

Contacts

Public ContactYukio Nakamura

Shinshu University School of Medicine Dept. of Orthopaedic Surgery

yxn14@aol.jp0263372659

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026